Fostemsavir
Based on 3 publication(s) in Google Scholar
Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.69%
- No. CAS: 864953-29-7
- Fòrmula: C25H26N7O8P
- Peso molecular:583.49
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15440
TemsavirHIV Inhibitor -
HY-13238
Dolutegravir -
HY-17431
Fosamprenavir Calcium SaltHIV-1 Inhibitor -
HY-13038A
FostamatinibSyk/FLT3 Inhibitor -
HY-111964
LenacapavirHIV-1 Capsid Inhibitor -
HY-17007
SaquinavirHIV Protease Inhibitor -
HY-14249
BicalutamideAndrogen Receptor Inhibitor -
HY-P0052
EnfuvirtideHIV-1 Fusion Inhibitor -
HY-17427
EmtricitabineNRT Inhibitor -
HY-16767
DoravirineNNRTI -
HY-N0842
BevirimatHIV Inhibitor -
HY-15592
CabotegravirHIV Integrase Inhibitor
Publications Citing Use of MedChemExpress (MCE) Fostemsavir
More
Actividad biológica
Descripciòn
IC50 & Target
|
HIV-1 |
In Vivo
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 864953-29-7
-
Appearance Solid
-
Peso molecular 583.49
-
Fòrmula C25H26N7O8P
-
Color White to off-white
-
SMILES
O=C(N1CCN(C(C2=CC=CC=C2)=O)CC1)C(C3=CN(COP(O)(O)=O)C4=C3C(OC)=CN=C4N5N=C(C)N=C5)=O
-
Synonyms
BMS-663068
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
-
J Chromatogr B Analyt Technol Biomed Life Sci
Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma. [Abstract]2025 Dec 15:1267:124803. PMID: 41072339
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (85.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 20 mg/mL (34.28 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 8.33 mg/mL (14.28 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.7138 mL | 8.5691 mL | 17.1383 mL | 42.8456 mL |
| 5 mM | 0.3428 mL | 1.7138 mL | 3.4277 mL | 8.5691 mL | |
| 10 mM | 0.1714 mL | 0.8569 mL | 1.7138 mL | 4.2846 mL | |
| 15 mM | 0.1143 mL | 0.5713 mL | 1.1426 mL | 2.8564 mL | |
| 20 mM | 0.0857 mL | 0.4285 mL | 0.8569 mL | 2.1423 mL | |
| 25 mM | 0.0686 mL | 0.3428 mL | 0.6855 mL | 1.7138 mL | |
| 30 mM | 0.0571 mL | 0.2856 mL | 0.5713 mL | 1.4282 mL | |
| DMSO | 40 mM | 0.0428 mL | 0.2142 mL | 0.4285 mL | 1.0711 mL |
| 50 mM | 0.0343 mL | 0.1714 mL | 0.3428 mL | 0.8569 mL | |
| 60 mM | 0.0286 mL | 0.1428 mL | 0.2856 mL | 0.7141 mL | |
| 80 mM | 0.0214 mL | 0.1071 mL | 0.2142 mL | 0.5356 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Fostemsavir Related Classifications
HY-15440A Related Classifications
Powered by Bioz